Wired News has an interesting discussion of a clinical stem cell trial
with the CEO of Geron, a California based stem cell company. The author takes time to discuss some of the process and hurdles that are faced by a company who wishes to engage in early clinical trials. From the article: "After an hour of speaking to Okarma, fears of a half-baked trial dissipated. He readily answered my many questions. If he didn't have the animal data to answer a query, he didn't try to dance around that fact. Okarma outlined a structured but malleable trial. I initially had reservations about safety, but Okarma emphasized that if the animal data is not good, the study will not move forward until problems are addressed."